The European Conference on Contrast Agent Science will take place in Mons, Belgium, from 19 to 21 May 2010.
The European Conference on Contrast Agent Science will take place in Mons, Belgium, from 19 to 21 May 2010.
Since 1988, the European MR Forum (EMRF) has arranged a series of biannual conferences focused on recent developments in image contrast enhancement by agents or tracers. The purpose of these meetings is to allow those interested in the field to get together to present their research in a setting that fosters discussion, collaboration, and advancement in the field. From the beginning, this group has been composed of both university scientists and representatives from industry.
The conference is organized on the principle of formal scientific exchange during the academic sessions and informal interaction during the rest of the day. Over the years, this has led to the development of new projects and products, often collaborative ones, between industry and academics or between universities. As always, the traditional mood of friendly and open exchange in Mons between the industrial and academic communities will be preserved.
EMRF's conferences are ongoing projects. Their continuity and success depend not only on the intellectual interest, contribution, and support of academics and commercial researchers in the field, as well as on financial support from the research branches of industry, but they also require the attention and input of scientists, radiologists, trainees, and other researchers who use, and improve, contrast agents of all kinds.
This is the first time since 1988 that EMRF requires abstract submissions. Abstracts should reach the scientific committee by 20 March 2010 (extended deadline). They should be attached to the submitter's conference registration.
For more information, please visit: EMRF Online.
AI Mammography Platform Shows Promising Results for Detecting Subclinical Breast Cancer
October 3rd 2024Mean artificial intelligence (AI) scoring for breasts developing cancer was double that of contralateral breasts at initial biennial screening and was 16 times higher at the third biennial screening, according to a study involving over 116,000 women with no prior history of breast cancer.
FDA Clears Software for Enhancing CCTA Assessment of Atherosclerosis
October 1st 2024Through analysis of coronary computed tomography angiography (CCTA) images, the PlaqueIQ software provides quantification and classification of atherosclerosis, a common cause of myocardial infarction (MI) and ischemic stroke.